Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia

ClinicalTrials.gov ID: NCT04172831

Public ClinicalTrials.gov record NCT04172831. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of TNX-102 SL Taken Daily At Bedtime In Patients With Fibromyalgia

Study identification

NCT ID
NCT04172831
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Enrollment
503 participants

Conditions and interventions

Conditions

Interventions

  • TNX-102 SL Drug
  • Placebo SL Tablet Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 8, 2019
Primary completion
Oct 28, 2020
Completion
Oct 28, 2020
Last update posted
Aug 7, 2022

2019 – 2020

United States locations

U.S. sites
39
U.S. states
25
U.S. cities
39
Facility City State ZIP Site status
Tonix Clinical Site Birmingham Alabama 35216
Tonix Clinical Site Phoenix Arizona 85016
Tonix Clinical Site Oceanside California 92056
Tonix Clinical Site Sacramento California 95831
Tonix Clinical Site San Diego California 92103
Tonix Clinical Site Temecula California 32591
Tonix Clinical Site Cromwell Connecticut 06416
Tonix Clinical Site Fort Myers Florida 33912
Tonix Clinical Site Jacksonville Florida 32256
Tonix Clinical Site North Miami Florida 33161
Tonix Clinical Site Ocala Florida 34470
Tonix Clinical Site Orlando Florida 32801
Tonix Clinical Site Atlanta Georgia 30341
Tonix Clinical Site Evansville Indiana 47714
Tonix Clinical Site West Des Moines Iowa 50265
Tonix Clinical Site Prairie Village Kansas 66208
Tonix Clinical Site New Orleans Louisiana 70115
Tonix Clinical Site Boston Massachusetts 02131
Tonix Clinical Site North Dartmouth Massachusetts 02747
Tonix Clinical Site Las Vegas Nevada 89102
Tonix Clinical Site Williamsville New York 14221
Tonix Clinical Site High Point North Carolina 27262
Tonix Clinical Site Raleigh North Carolina 27612
Tonix Clinical Site Fargo North Dakota 58104
Tonix Clinical Site Cincinnati Ohio 45219
Tonix Clinical Site Dayton Ohio 45417
Tonix Clinical Site North Canton Ohio 44720
Tonix Clinical Site Oklahoma City Oklahoma 73112
Tonix Clinical Site Tulsa Oklahoma 74133
Tonix Clinical Site Portland Oregon 97210
Tonix Clinical Site Allentown Pennsylvania 18104
Tonix Clinical Site Warwick Rhode Island 02886
Tonix Clinical Site Chattanooga Tennessee 37421
Tonix Clinical Site Memphis Tennessee 38119
Tonix Clinical Site Austin Texas 78737
Tonix Clinical Site Dallas Texas 75231
Tonix Clinical Site Salt Lake City Utah 84102
Tonix Clinical Site Charlottesville Virginia 22911
Tonix Clinical Site Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04172831, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 7, 2022 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04172831 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →